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REZUMAT
TULBURARE MUSCULARĂ LEGATĂ DE COLAGEN VI. DISTROFIA MUSCULARĂ CONGENITALĂ 
ULLRICH. RAPORT DE CAZ
Colagenul tipul VI este un colagen microfibriliar localizat in matrixul extracelular predominant de tesuturi conjuctive. 
Este compus din 3 lanturi α codate de trei gene independente. Mutatiile in aceste gene provoaca maladii musculare de 
un anumit grup care pot fi referiti ca miopatii lincate de colagenul VI. Aceste miopatii cuprind un spectru de maladii 
ce cuprind cazuri de la cele mai severe cazuri precum distrofia musculara congenitala Ullrich (DMCU) urmat de 
fenotipuri de tranzitie severa spre miopatia mai usoara Bethlem (MB). In aditie, fenotipul contractural, referit drept 
mioscleroza, este cunoscut si asociat cu mutatia in gena COL6A2. DMCU a fost initial descris intr-o serie de articole 
din anii 1930 de catre Otto Ullrich, care sa referit la conditie drept, distrofia musculara atonica-sclerotica cu progresul 
contracturilor. MB a fost descrisa in 1976 de catre Bethlem si van Wijngaarden drept o conditie autosomal dominanta 
gasita in 28 de indivizi din cadrul a 3 familii Olandeze, acesti indivizi avand specific contractii de flexie a degetelor.
In acest articol noi descriem un caz a unui pacient Moldovean cu fenotip clinic de DMCU si rolul colagenului VI in 
patogeneza acestuia. 
РЕЗЮМЕ
КОЛЛАГЕНОПАТИЯ VI ТИПА. БОЛЕЗНЬ УЛЬРИХА. КЛИНИЧЕСКИЙ СЛУЧАЙ. 
Коллаген шестого типа представляет собой микрофибриллярный коллаген, локализованный в матриксе 
большинства соединительных тканей. Он состоит из трёх альфа цепей, кодирующихся тремя отдельными 
генами. Мутации в этих генах приводят к заболеваниям, известным как миопатии, связанные с коллагеном 
шестого типа. Эти миопатии включают в себя широкий спектр заболеваний, начиная от самых тяжёлых 
по типу врождённой мышечной дистрофии Ульриха (ВМДУ) через серию фенотипов переходной тяжести 
к более лёгкой миопатии Бетлема (МБ). Также известен преимущественно контрактурный фенотип, 
называемый миосклерозом и связанный с мутациями в гене COL6A2. ВМДУ была впервые описана Отто 
Ульрихом в серии статей, опубликованной в 1930-х годах, где он называл её «атоническо-склеротической 
мышечной дистрофией» с прогрессирующими контрактурами. МБ была описана в 1976 году Бетлемом и ван 
Винжгаарденом как аутосомно-доминантно наследуемое заболевание. Описание было составлено на основе 
анализа 28 больных из трёх голландских семей, имевших сгибательные контрактуры пальцев.
В этой статье мы описываем клинический случай молдавского пациента с клиническим фенотипом ВМДУ и 
роль коллагена шестого типа в патогенезе болезни.
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Introduction. Collagen type VI is a microfibrillar 
collagen found in many extracellular matrices including 
those of muscle, skin, tendon, and vessels. It is composed 
of three α chains encoded by three independent genes 
on chromosomes 2 and 21. Mutations in these three 
genes have been found to underlie a group of muscle 
disorders that are now referred to as collagen VI-related 
myopathies. These myopathies encompass a spectrum of 
disorders ranging from the more severe Ullrich congenital 
muscular dystrophy (UCMD) through transitional 
severity phenotypes to the milder Bethlem myopathy 
(BM). An additional, mostly contractural phenotype, 
referred to as myosclerosis, has also been delineated 
and associated with mutations in COL6A2 [1]COL6A2, 
and COL6A3, coding for three α chains of collagen type 
VI, underlie a spectrum of myopathies, ranging from 
the severe congenital muscular dystrophy-type Ullrich 
(UCMD. UCMD was initially described in a series of 
papers in the 1930s by Otto Ullrich, who referred to 
the condition as “atonic-sclerotic muscular dystrophy” 
because of the characteristic occurrence of weakness 
and striking joint hypermobility (“atony” in the original 
description) in conjunction with significant and evolving 
contractures (“sclerotic”). After collagen VI mutations 
had been identified in BM it was the realization by Enrico 
Bertini and Mimma Pepe in 2001 in Italy that some of the 
clinical features in UCMD were reminiscent of BM that 
led to the first discovery of collagen VI mutations in this 
condition as well [2] [3]. UCMD is classically described 
as an autosomal recessive condition. It is a clinically and 
genetically distinct entity within the congenital muscular 
dystrophy. Bethlem myopathy was first described in 
1976 by Bethlem and van Wijngaarden as an autosomal 
dominantly inherited mild proximal myopathy with long 
finger flexion contractures occurring in 28 individuals of 
three Dutch pedigrees [4]. In this article we present case 
report of Modavian’s patient with clinical phenotypes 
of Ullrich congenital muscular dystrophy (UCMD1, 
MIM254090) and the role of collagen VI in causation.
Case report. Patient A. (P.A.), born at 2017 parents 
addressed at geneticist in center of reproductive health and 
medical genetics in Chisinau, Republic of Moldova when 
child had 2 months of age. Main accusations: weakness 
and spine deformation. Parents are not consanguineous. 
Parent’s age: mother – 34 years old, father – 41 years old. 
Pedigree is not burdened by the maternal and paternal 
lines, but both parents are above average height.
It was first pregnancy, without pathologies. Was born at 
39 weeks gestational age with breech presentation, was 
born through cesarean section. Weight after birth was 
3200 gramms. Height - 56 cm. Appgar 8/8. From the birth 
patient had ankiloglosia, congenital hydrocele, bilateral 
congenital hip subluxation, muscle weakness. Vaccinated 
in correspondence with Republic of Moldova national 
vaccination plan. Feeding is natural. After the first two 
months added 2686 gramms of weight.
At 1 month of age parents addressed to neurologist 
because of torticollis and at the age of 2 moths — at 
geneticist. At 2 months of age: clear and palid skin, 
skull is brachycephalic, arachnodactylia, transverse fold 
of the hand, muscular torticollis at right and severe 
kyphoscoliosis; neurological state — pronounced 
hypotonia, more at upper shoulder girdle, distal upper 
and lower limbs muscles hypotrophy, hyporeflexia. The 
phenotype was suggestive of a myopathy, particularly of 
Ullrich Congenital muscular dystrophy (UCMD1, MIM 
254090) 
Biochemical blood analysis performed at 1 moth of age 
revealed: rised homocysteine -10 uM (ref 3.0-6.0), total 
bilirubine- 58.8 (ref<20.0) uM, direct bilirubine- 8.44(N 
0.0-3.4) uM, ionic calcium, iCa++- 1.43 (N 1.13-1.32) 
uM, potassium, K - 5.34 (N 3.5-5.3) uM, AST 118.0 (N 
13.0-45.0) U/L; decreased sodium, Na-132.80 (N 137.0-
145.0) uM, pancreatic alpha(α)-amylase - 5.2 (13.0-
53.0) U/L. Total calcium, Ca++- 2.55(N 2.14-2.57) uM, 
clorine, Cl – 103.20 (N 98.0-107.0) uM, phosphorous, 
P- 1.98 (N1.29-2.26) uM, ALT- 60 (15.0-60.0) U/L were 
within reference range for corresponding age. At 2 moths 
remained rise of direct (13.8 uM) and total bilirubine 
(37,6 uM), homocysteine levels rised up to 17,5 uM. 
There was unsignificant rise of total creatin kynase (СК) 
204,0 (ref 0.0-171.0 U/L, CK-MB 27.0 (ref 0.0-25.0) 
U/L; LDH was within reference range 259,0 (0-430) 
U/L. There was rise of CK level upto 433,0 and CK-MB 
up to 74,00 at the age of one year.
USG performed May 2017 (at 2 months) – size and 
echo structure of liver, pancreas and spleen are within 
corresponding age reference age. Kidneys are placed 
in typical place, without echoscopically determined 
pathologies.
NMR (Magnetom Siemens Essenza 1.5 Tesla) of the 
cervical, thoracic and lumbar spinal cord (“whole spine” 
regime, w/o contrast) performed May 2017 discovered a 
diffuse, fusiform, pseudotumoral formation in right m. 
Sternocleidomastoideus - caracteristic for fibromatosis 
colli. Cervico-toraco-lombar S-type scoliosis of moderate 
grade. 
Electromyography performed May 2017- 
electrophysiological indexes within reference range.
At May 2017 was performed search of exons 7 & 8 
deletions in SMN1 gene using PCR-RFLP method 
(Chisinau, Moldova). No deletions were revealed, spinal 
muscular atrophy excluded. 
PCR-RFLP analysis (performed in Moldova) of folate 
and methyonine cycles genes (MTHFR, MTR, MTRR, 
CBS) revealed heterozygous polymorphisms MTHFR 
C677T, A1298C and MTR A2756G, what explains high 
homocysteine concentration at child. 
Whole-exome sequencing and data analysis was 
performed in University Medical Centre Hamburg-
Eppendorf, Germany at June 2019. Coding regions 
including surrounding intronic sequences (+/-10 bp) 
were isolated and enriched out of the whole genome from 
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the three DNAs of the family proband and his parents 
using in-solution technology Sure SelectXT Human Al 
Exon V6 (Agilent). NGS was performed by using the 
Illumina HiSeq® platform at CeGaT, Tübingen, Germany. 
Sequencing data were bioinformatically analyzed via in-
house pipeline for all inheritance patterns and aligned to 
the human reference genome (hg19). Has been performed 
variant validation through PCR amplification of exon 7 
of the COL6A2 gene, exon 33 of the RYR1 gene, exon 7 
of the SSR4 gene and exons 35 and 36 of the EIF2AK4 
gene as well as adjacent intronic sequences from the 
three aforementioned DNA samples. Directly sequenced 
the PCR products have been performed by using an 
automatic sequencer (Applied Biosystems ABI 3500). 
The obtained sequenced were evaluated by the Sequence 
Pilot SeqPatient Software (JSI medical systems GmbH) 
and compared to the reference sequences in the database 
(mRNA reference number: COL6A2, NM_001849.3; 
RYR1, NM_001204526.1; EIF2AK4, NM_001013703.4).
Results of Whole-exome sequencing. To identify 
the genetic cause of PA.’s muscular disease, have been 
analyzed the exomes of the family using a bioinformatics 
filtering for harboring de novo variants, which are 
potentially pathogenic and have not been described in the 
general population (dpSNP 138, 1000 Genomes Project, 
Exome Variant Server, ExAC browser, and gnomAD 
browser). This analysis lad to the identification of a 
missense variant in COL6A2 (MIM 010240), the disease 
gene for Bethlem myopathy (BTHLM1, MIM 158810) 
and Ullrich congenital muscular dystrophy (UCMD1, 
MIM 254090). Also, had identified a second missense 
variant in RYR1 (MIM 180901), the disease genefor 
central core disease (CCD, MIM117000), malignant 
hyperthermia (MIM 145600) and minicore myopatyhy 
with external ophtalmoplegia (MMD, MIM 255320). The 
genetic variants were validated in Alexandu’s DNA in 
the heterozygous state using Sanger sequencing. Neither 
his mother nor his father carried the variants in the 
DNA. Therefore, the missense variants in COL6A2 and 
RYR1 occurred de novo in P.A.: COL6A2: c.874G>T/p. 
(Gly292Cys) & RYR1: c.4855G.A/p .(Ala1619Thr).
Also, have been analyzed the exome data based on an 
autosomal recessive inheritance model with homozygous 
or compound heterozygous variants and no homozygotes 
in P.A. The minor allele frequency of ≤0.1% in population 
databases (dpSNP138, 1000 Genomes Project, Exome 
variant Server, ExAC Browser and gnomAD Browser). 
P.A.’s parents are heterozygous carriers of the variants. 
Have been identified compound heterozygous variants in 
EIF2AK4 (MIM 609280), the disease gene for pulmonary 
venoocclusive disease 2 (MIM 234810). These variants 
were validated by Sanger-sequencing and to be in trans in 
the DNA of P.A. as his mother and father were shown to 
be heterozygous carriers for one of two variants. 
EIF2AK4: c.4669C>T/p.(Arg1557*)- paternally inherited
EIF2AK4: c.4646G>A/p.(Arg1549His)- maternally inherited
Exome data were also analyzed based on an 
X-chromosomal inheritance model with hemizygous 
variants in population databases and no herizygotes 
in P.A. and his mother is a heterozygous carrier of the 
respective X-linked variant in SSR4 (MIM 300090), the 
disease gene for congenital disorder of glycosylation 
(CDG1Y, MIM300934). The variant was validated in the 
hemizygous state in the DNA of P.A., and his mother is a 
heterozygous carrier of the variant.
SSR4: c.454A>G/p.(Thr152Ala) – X-linked, maternaly inherited
Discussion. By molecular genetic analysis have been 
identified the heterozygous de novo missense variant 
c874G.T/p (Gly292Cys) in the gene COL6A2, in which 
heterozygous or biallelic variants cause BTHLM1 and 
UCMD1. Based on database and literature searches we 
interpret this variant to be the main genetic cause for the 
observed muscular disease in P.A.. The identified de novo 
missense variant c.874G>T/p.(Gly292Cys) is predicted to 
be damaging by all pathogenicity prediction programs. 
Heterozygous variants in COL6A2 are associated with 
autosomal dominant BTHLM1 autosomal dominant 
UCMD1. Bethlem and van Wijngaarden (1976) 
described the phenotype of Bethlem myopathy (BM) as 
a benign myopathy with an early infancy onset and slow 
progression. Constant findings in patients are moderate 
weakness, atrophy of trunk and limb muscles, early 
flexion contractures of elbows and interphalangeal joints 
of the last four fingers, and planter flexion contractures 
of the ankles. In comparison, the haalmarrks of UCMD 
are muscle weakness of early onset with proximal joints 
contractions and striking hyperelasticity of distal joints 
and normal intelligence [4]. The observed kyphoscoliosis 
in P.A. is found in pationts with UCMD1 and has been 
reported as a typical feature of UCMD1 [5]. P.A.’s 
phenotype shows overlap with both forms of COL6A2-
related myopathies. 
COL6A2 encodes the α2 chain of collagen VI. Collagen 
VI consists of three district α-chains (α1, α2, α3). All 
three chains contain a central short triple helical domain 
of 335 to 336 amino acids with repeating Gly-Xaa-Yaa 
sequences, flanked by two large N- and C-terminal 
globular domains made up of motifs of 200 amino acids 
each, which are homologous to von Willebrand factor 
(vWF) type A domains 60–64 (Fig. 1). COL6A1, which 
consists of 37 exons (35 coding), contains one promoter 65 
and produces a single transcript (NM_001848) encoding 
a protein of 1021 amino acids (NP_001839) with two 
C-terminal and one N-terminal vWF type A-like domains 
[4]. Alteretion within Gly-Xaa-Yaa triplets descript the 
multimerization of collagenVI into microfibrila [6]
Disease-associated amino acid subsitutions affecting 
Cly292 are listed in the HGMD database: c.875G>A/p.
(Gly292Asp), c874G>A/p.(Gly292Ser), c.875G>T/p.
(Gly292Val). These domimant variant have been 
associated with intermediate and moderate progressive 
forms of UCMD1 [6][7][8].
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Autosomal dominantly acting missense variant associated 
with UCMD1 mainly cluster in the T-terminal region of 
the triple helical domain (TH) (Fig.1). The indentified 
variant p.(Gly292Cys) most likely disrupts one Gly-
Xaa-Yaa triplet in the highly conserved TH domain. 
Heterozygous glycine substitution have been reported in 
early-severe UCMD phenotyps(c.833G>T/p.Gly278Val; 
c.850G>A/p.Gly284Arg; c.887G>T/p.Gly296Val) [7], 
however, clinica; variability ranges from severe UCMD1 
and intermediate to mild BTHLM1 phenotypes [4], [6]
The identified amino acid substitution p.(Gly292Cys) 
in P.A. is located in triplet 13. Pace et al. have suggested 
that patients with glycine substitutions in a critical 
region including Gly-X-Y triplets 10-15 have a more 
severe disruption of collagen VI assembly and a more 
severe clinical phenotype [9] because to be of particular 
impotance for microfibril formation. In Butterfield’s 
cohort, patients with mutations inside the critical region 
tend to a more severe phenotype with 48% ES-UCMD or 
typical UCMD compared to 23% ES-UCMD or typical 
UCMD in cases with mutations outside the critical 
region. Patients with glycine substitutions outside the 
critical region tended toward a milder phenotype with 
40% BM compared to 7% BM in patients with mutations 
inside the critical region [6]
In addition, have been identified variants of unknown 
significance (VUS) in two disease genes: 
 • A de novo missense variant of unknown significance 
in the disease gene RYR1
 • And compound heterozygous variants in EIF2AK4, 
one likely pathogenic allele and a second variant 
which were interpret as VUS
The heterozygous de novo RYR1variant c.4855G>A 
predicts the amino acid subctutution p.(Ala1619Thr), and 
three of six pathogenicity prediction programs (CADD, 
REVEL, M-CAP, SIFT, Polyphen2 and MutationTaster) 
predict the variant to be possibly damaging.
Ryanodine receptor gene (RYR1) mutations have 
been associated withare associated with two different 
neuromuscular disorders: central core disease (CCD) and 
multiminicore/minicore/multicore disease (MmD), and 
susceptibility to malignant hyperthermia (MH). RYR1 
encodes the principal sarcoplasmic reticulum calcium 
release channel and has been implicated in various 
congenital myopathies [9].
Fig.1. Genomic organisation of collagen VI and localisation of genomic changes reported for BM and UCMD to 
date; modification from Chu et al. The triple helical domains contain a single cysteine residue (depicted as “C”) 
which is important for dimer assembly. The localisation of the genomic changes reported for BM and UCMD to 
date is shown stratified by clinical phenotype.The p.(Gly292Cys) change identified in P.A. is indicated in orange. 
Figure adapted from Lampe and Bushby (2005) [4].
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CCD is caused by heterozygous or bialelic variant in 
RYR1, while MMD is an autosomal resessive disorder. The 
disease-associated variants cluster in three mutational 
hotspot regions of RYR1 [10]the molecular causes remain 
unknown for nearly half of the patients, due to genetic 
heterogeneity and conventional molecular diagnosis 
based on a gene-by-gene approach. We aimed to test next 
generation sequencing (NGS The variant found in P.A.’s 
DNA, c.4855G>A, is located in exon 33, which is outside 
the three mutation clusters. CCD is a relatively mild 
congenital myopathy, characterized by developmental 
delay and mild proximal weakness, most pronounced 
in the hip-girdle muscular. Orthopedic complications, 
including dislocation of hips and scoliosis, are common. 
The Phenotype of P.A. shows some overlap with CCD.
Biallelic variants in the eukaryotic initiation factor 2 alpha 
kinase 4 (EIF2AK4) gene cause heritable pulmonary 
veno-occlusive disease (PVOD)/pulmonary capillary 
haemangiomatosis (PCH), a rare cause of pulmonary 
hypertension [11], that is characterized histologically by 
widespread fibrous intimal proliferation of septal veins 
and preseptal venules and is frequently associated with 
pulmonary dilatation and proliferation. Penetrance is 
unknown [12]. PVOD/PCH due to EIF2AK4 mutations 
can occur from birth to age 50 years (median 26 years 
(range 0-50.3))[13]. Multiple disease causing variants 
have been identified in patients with PVOD. The majority 
of disease-relevant variants are truncating or insertion/
deletion variants which are predicted to disrupt protein 
function [11].
The paternally inherited nonsense variant c.4669C>T/p.
(Arg1557*) has s worldwide allele frequency of 0,000012 
(three heterozygous carriers in gnomAD browser). 
The variant is not listed as a known disease causing 
variant in the HGMD database or the ClinVar database. 
Nometheless, this variant likely represents a loss-of 
–function variant and therefore a pathogenic allele. 
The maternally inherited missense variant c.4646G>A 
predicts the amino acid substitution p.(Arg1549His) and 
is predicted to be possibly damaging by four of six in silico 
tools (CADD, REVEL, M-CAP, SIFT, POlyPhen2 and 
MutationTaster). The missense variant has a worldwide 
allele frequency of 0,000785, which represents 22 
heterozygous carriers in gnomAD browser. To rule out 
an effect on splicing by the missense variant, splice site 
predictions were performed. The four programs did not 
predict an alteration of EIF2AK4 pre-mRNA splicing.
The c.4646G>A variant has been observed in an individual 
with primary pulmonary arterial hypertension (PAH) in 
the heterozygous state. However, whether heterozygous 
EIF2AK4 variants contribute to the aetiology of PAH is 
currently unclear [12],[13].
Also, a hemizygous variant c.454A>G in SSR4 gene 
indentified in P.A. could be interpret as a likely benign 
variant for the following reasons: This variant predicts 
the amino acid substitution p,(Thr152Ala). Only one 
of six pathogenicity prediction programs (CADD, 
REVEL, M-CAP, SIFT, Polyphen2 and Mutation Taster) 
predicts the variant to be possibly damaging. Variants 
in SSR4 are associated with CDG1Y. SSR4-CDG is a 
form of congenital disorders of N-linked glycosylation 
characterized by neurologic abnormalities (global 
developmental delay in language, social skills and fine 
and gross motor development, intellectual disability, 
hypotonia, microcephaly, seizures/epilepsy), facial 
dysmorphism (deep set eyes, large ears, hypoplastic 
vermillion of upper lip, large mouth with widely spaced 
teeth), feeding problems often due to chewing difficulties 
and aversion to food with certain textures, failure to 
thrive, gastrointestinal abnormalities (reflux or vomiting) 
and strabismus [14]. This phenotype (except hypotonia) 
does not overlap with the phenotype of P.A..
Conclusion. Have been indentified the de novo missense 
variant c.874G>T/p.(Gly292Cys) in COL6A2 gene. 
Due to known disease-associated variants in COL6A2 
(affecting the same codon), the reported genotype-
phenotype correlation, and P.A.’s phenotype this variant 
most likely underlies his muscular process. In addition, 
have been identified variants of unknown significance 
in two additional disease genes. Whether or not these 
variants contributed to P.A.’s current phenotype or will 
cause other clinical features in the future cannot be 
predicted to date:
1. The heterozygous de novo RYR1 missense variant 
c4855G>A/ p.(Ala1619Thr) could not exclude a 
possible association of this variant with malignant 
hyperthermia. That is why, we prophylactically 
recommended to avoid any anesthetic agent know 
to trigger malignant hyperthermia, which seems 
to be even more important because of the proven 
neuromuscular disorder of P.A.
2. The likely pathogenic, paternally inherited variant 
c.4669C.T/p.(Arg1557*) and the maternally inherited 
variant of unknown significance c.4646G>A/ 
P.(Arg1549His) in EIF2AK4 although show a 
prediction to PVOD, which is currently not proven. 
But we recommended regular respective clinical 
investigations in P.A. and will perform multiple 
isoelectric focusing for determination abnormal/
normal carbohydrate deficient transferrin profile and 
electrospray mass spectrometry analyses. 
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